The report by Crawford et al makes little mention of sources of error in their study. The General Practices involved were selected twice; first by responding to the research team at all, and secondly by speed of response. Only 40 of 556 Practices made it over both hurdles! This would seem an effective means of selecting 40 Practices with an enthusiastic interest in epilepsy. What were the policies of the Practices who entered the study on generic prescribing for epilepsy?
From these practices 2285 people with epilepsy were contacted and asked to complete a questionnaire, of whom 58.8% responded. A switch of anticonvulsant, from generic to brand or brand to generic, was experienced by 251 people but we are not told from the GPs' records how many switches actually occurred or what proportion of switches were generic to brand. Patients who perceived problems would be more likely to respond to the questionnaire and to remember switches.
The basis for the claim that switches produced significant health problems is not clear. Increased sick leave and loss of employment are discussed, but the study gives no data on whether patients who perceive problems during the switch consulted their GPs or missed time off work. The basis for the GPs 'validating' problems after the switch is not clear.
A critical eye might perceive that, starting with the epilepsy population of the Yorkshire region-perhaps 20000 patients, this study identified 21 people who felt poorly at a time which coincided with a switch of medication.
Epilepsy is a very variable condition. Seizures change in frequency unpredictably even on constant medication. People with epilepsy are as subject to the placebo influence of changes in their medication as anyone else. UncontrolIed and highly selected reports do nothing to inform the debate about generic prescribing. 
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